| Zhu, Kangshun |
NCT06492395: Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTT |
|
|
| Recruiting | 3 | 178 | RoW | Len+DEB-TACE+HAIC, Len+DEB-TACE | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 07/26 | 07/27 | | |
| Recruiting | 3 | 230 | RoW | dTACE-HAIC, HAIC, dTACE-HAIC protocol, Drugs for DEB-TACE and HAIC, HAIC protocol, Drugs for HAIC | Second Affiliated Hospital of Guangzhou Medical University, Hainan General Hospital, Maoming People's Hospital, Zhongshan People's Hospital, Guangdong, China, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan, Jiangmen Central Hospital, First Affiliated Hospital, Sun Yat-Sen University | Unresectable Hepatocellular Carcinoma | 02/26 | 02/26 | | |
NCT05608213: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC |
|
|
| Recruiting | 3 | 187 | RoW | Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 10/26 | 12/26 | | |
NCT05608200: Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC |
|
|
| Recruiting | 3 | 427 | RoW | Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 10/26 | 10/26 | | |
NCT04627363: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama |
|
|
| Not yet recruiting | 2 | 30 | NA | Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Bevacizumab, Liver Neoplasms, Toripalimab, Oxaliplatin | 06/22 | 06/23 | | |
| Recruiting | 2 | 30 | RoW | Donafenib+sintilimab | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma | 05/23 | 05/23 | | |
REGSIN, NCT04718909: Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC |
|
|
| Active, not recruiting | 2 | 166 | RoW | Regorafenib + sintilimab, Regorafenib | Second Affiliated Hospital of Guangzhou Medical University, ZhuHai Hospital, Shenzhen People's Hospital, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Zhaoqing, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guangxi Medical University, Jiangmen Central Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Peking University Shenzhen Hospital, Jieyang People's Hospital, Shantou Central Hospital, Yuebei People's Hospital, Zhaoqing Gaoyao People's Hospital | Hepatocellular Carcinoma Non-resectable | 07/23 | 12/23 | | |
NCT06397222: Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC |
|
|
| Recruiting | 2 | 23 | RoW | Sin-Bev-SIRT | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 04/27 | 04/27 | | |
| Recruiting | 2 | 130 | RoW | DEB-TACE+HAIC, DEB-TACE | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 04/27 | 04/28 | | |
NCT06001567: Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC |
|
|
| Recruiting | 2 | 30 | RoW | Avatrombopag | Second Affiliated Hospital of Guangzhou Medical University | Thrombocytopenia, Hepatocellular Carcinoma | 08/24 | 08/24 | | |
| Recruiting | 2 | 33 | RoW | SIRT | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-Resectable | 11/26 | 11/27 | | |
NCT05992584: Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC |
|
|
| Recruiting | 2 | 30 | RoW | Lenvatinib, sintilimab plus SIRT | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma | 01/26 | 08/26 | | |
NCT04592029: TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC |
|
|
| Active, not recruiting | 1 | 36 | RoW | TACE combined with sintilimab and bevacizumab | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 06/22 | 12/22 | | |
NCT04640116: TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites |
|
|
| Not yet recruiting | N/A | 30 | NA | Transjugular intrahepatic portosystemic shunt (TIPS), microwave ablation (MWA) | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Liver Diseases, Portal Hypertension, Cirrhosis, Liver, Ascites, Hepatocellular Carcinoma | 08/21 | 06/23 | | |
NCT03322280: TACE Combined With Iodine-125 Seeds Implantation for HCC |
|
|
| Active, not recruiting | N/A | 270 | RoW | TACE combined with iodine-125 seeds implantation, TACE | Second Affiliated Hospital of Guangzhou Medical University, ZhuHai Hospital, The First People's Hospital of Zhaoqing, Foshan Sanshui District People's Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, Sun Yat-sen University, Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus | 09/21 | 06/22 | | |
NCT04618367: HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT |
|
|
| Completed | N/A | 30 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, TKI inhibits, Sintilimab, programmed cell death protein-1 (PD-1) antibody | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus | 12/21 | 12/22 | | |
NCT06712017: Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China |
|
|
| Enrolling by invitation | N/A | 100 | RoW | Yttrium-90 (Y-90) resin microspheres | GrandPharma (China) Co., Ltd. | Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable | 12/24 | 06/25 | | |
| Recruiting | N/A | 35 | RoW | SIRT | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma | 08/26 | 02/27 | | |
